The Enigmata of Cardioprotection With SGLT2 Inhibition
JACC Basic to Translational Science,
Год журнала:
2025,
Номер
10(1), С. 62 - 64
Опубликована: Янв. 1, 2025
Язык: Английский
Anti-inflammatory Therapies for Ischemic Heart Disease
Current Cardiology Reports,
Год журнала:
2025,
Номер
27(1)
Опубликована: Фев. 19, 2025
Abstract
Purpose
of
Review
The
inclusion
immunomodulatory
strategies
as
supportive
therapies
in
ischemic
heart
disease
(IHD)
has
garnered
significant
support
over
recent
years.
Several
such
approaches
appear
to
be
unified
through
their
ultimate
target,
the
NLRP3
inflammasome.
This
review
presents
a
brief
update
on
continuum
conditions
constituting
and
emphasising
seemingly
unifying
mechanism
activation
well
modulation
across
these
conditions.
Recent
Findings
inflammasome
is
multiprotein
complex
assembled
upon
inflammatory
stimulation,
causing
release
pro-inflammatory
cytokines
initiating
pyroptosis.
pathway
relevant
signalling
cardiac
immune
cells
non-immune
myocardium,
including
cardiomyocytes,
fibroblasts
endothelial
cells.
In
addition
focus
clinical
outcome
efficacy
trials
targeting
NLRP3-related
pathways,
potential
connection
between
immunomodulation
cardiology
currently
being
explored
preclinical
trials.
Colchicine,
cytokine-based
SGLT2
inhibitors
have
emerged
promising
agents.
However,
comprising
IHD
atherosclerosis,
coronary
artery
(CAD),
myocardial
infarction
(MI)
cardiomyopathy/heart
failure
(iCMP/HF)
are
not
equally
amenable
with
respective
drugs.
Atherosclerosis,
cardiomyopathy
affected
by
chronic
inflammation,
but
approach
acute
inflammation
post-MI
setting
remains
pharmacological
challenge,
detrimental
regenerative
effects
initiated
unison.
Summary
lies
at
center
cell
mediated
IHD.
trial
evidence
highlighted
anti-inflammatory
colchicine,
interleukin-based
therapy
SGLT2i
that
drugs
modulate
Язык: Английский
Sodium-glucose co-transporters (SGLT2) inhibitors prevent lipid droplets formation in vascular inflammation or lipid overload by SGLT2-independent mechanism
Biomedicine & Pharmacotherapy,
Год журнала:
2025,
Номер
185, С. 117967 - 117967
Опубликована: Март 14, 2025
Язык: Английский
Is boosting OXPHOS/FAO gene pathways the final end-mechanism of SGLT2i protection?
Journal of Molecular and Cellular Cardiology Plus,
Год журнала:
2025,
Номер
unknown, С. 100297 - 100297
Опубликована: Апрель 1, 2025
Язык: Английский
Direct Cardiac Mechanisms of the Sodium Glucose Co-Transporter 2 Inhibitor Class
Journal of Cardiovascular Pharmacology and Therapeutics,
Год журнала:
2025,
Номер
30
Опубликована: Апрель 1, 2025
BackgroundSodium-glucose
co-transporter
2
(SGLT2)
inhibitors
have
demonstrated
significant
cardiovascular
benefits
in
clinical
trial.
While
their
role
reducing
heart
failure
hospitalizations
and
mortality
is
well
established,
the
precise
mechanisms
underlying
direct
cardiac
effects
remain
unclear.
This
literature
review
aims
to
synthesize
current
knowledge
on
molecular
physiological
pathways
by
which
SGLT2
may
exert
tissue,
independent
of
glycemic
control.MethodsA
comprehensive
peer-reviewed
articles,
randomized
controlled
trials,
meta-analyses,
mechanistic
studies
published
PubMed
related
databases
was
conducted.
The
search
focused
examining
impact
function,
remodeling,
metabolism,
intracellular
signaling
pathways.
Only
evaluating
separate
from
glucose-lowering
action
were
included
analysis.ResultsThis
identified
several
key
benefit
directly,
including
reductions
oxidative
stress,
inflammation,
myocardial
fibrosis.
Emerging
evidence
suggests
that
these
drugs
modulate
such
as
sodium-hydrogen
exchange
(NHE)
inhibition,
improvement
mitochondrial
promotion
ketone
body
utilization
cardiomyocytes.ConclusionsSGLT2
appear
confer
cardioprotective
effects.
These
include
anti-inflammatory,
anti-fibrotic,
energy
efficiency
improvements
myocardium.
findings
highlight
new
potential
therapeutic
provide
a
foundation
for
further
research
into
non-diabetic
use
other
conditions.
Understanding
could
lead
optimized
treatment
strategies
patients
with
without
diabetes.
Язык: Английский
ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling
Cardiovascular Diabetology,
Год журнала:
2024,
Номер
23(1)
Опубликована: Окт. 26, 2024
Sodium-glucose
cotransporter-2
inhibitors
(SGLT2i)
are
now
recommended
for
patients
with
heart
failure,
but
the
mechanisms
that
underlie
protective
role
of
SGLT2i
in
cardiac
remodeling
remain
unclear.
Aldehyde
dehydrogenase
2
(ALDH2)
effectively
prevents
remodeling.
Here,
key
ALDH2
efficacy
on
was
studied.
Язык: Английский
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Guardians against Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Heart Diseases
ACS Pharmacology & Translational Science,
Год журнала:
2024,
Номер
7(11), С. 3279 - 3298
Опубликована: Окт. 16, 2024
Sodium-glucose
cotransporter
2
(SGLT2)
inhibitors
are
an
innovative
class
of
antidiabetic
drugs
that
provide
cardiovascular
benefits
to
both
diabetic
and
nondiabetic
patients,
surpassing
those
other
drugs.
Although
the
roles
mitochondria
endoplasmic
reticulum
(ER)
in
research
increasingly
recognized
as
promising
therapeutic
targets,
exact
molecular
mechanisms
by
which
SGLT2
influence
mitochondrial
ER
homeostasis
heart
remain
incompletely
elucidated.
This
review
comprehensively
summarizes
discusses
impacts
on
dysfunction
stress
diseases
including
failure,
ischemic
disease/myocardial
infarction,
arrhythmia
from
preclinical
clinical
studies.
Based
existing
evidence,
effects
may
potentially
involve
restoration
biogenesis
alleviation
stress.
Such
consequences
achieved
enhancing
adenosine
triphosphate
(ATP)
production,
preserving
membrane
potential,
improving
activity
electron
transport
chain
complexes,
maintaining
dynamics,
mitigating
oxidative
apoptosis,
influencing
cellular
calcium
sodium
handling,
targeting
unfolded
protein
response
(UPR)
through
three
signaling
pathways
inositol
requiring
enzyme
1α
(IRE1α),
kinase
R
like
(PERK),
activating
transcription
factor
6
(ATF6).
Therefore,
have
emerged
a
target
for
treating
due
their
potential
improve
functions
Язык: Английский
Effectiveness and mechanisms of sodium-dependent glucose transporter 2 inhibitors in type 2 diabetes and heart failure patients
World Journal of Cardiology,
Год журнала:
2024,
Номер
16(10), С. 611 - 615
Опубликована: Окт. 17, 2024
We
comment
on
an
article
by
Grubić
Rotkvić
Язык: Английский
Comparative efficacy study of experimental chronic heart failure
Drug development & registration,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 26, 2024
Introduction.
Combination
therapy
of
chronic
heart
failure
(CHF)
is
an
urgent
and
important
treatment
strategy,
as
it
allows
to
achieve
improvement
in
the
prognosis,
optimal
control
symptoms
disease
increase
quality
life
patients.
Aim.
Comparison
effectiveness
malonic
acid
derivative
ethmaben,
sodium-glucose
cotransporter
inhibitor
empagliflozin
their
combinations
with
variability
starting
drug
experimental
post-infarction
rats.
Materials
methods.
In
a
model
failure,
reproduced
by
permanent
ligation
left
coronary
artery
rats,
echocardiographic
study
was
used
compare
etmaben
monotherapy
combined
regimen
these
drugs.
The
concentration
myocardium
assessed
HPLC.
Results
discussion.
Antagonism
between
revealed,
manifested
decrease
effect
combination
relation
any
components,
under
action
type
2
shown.
Conclusion.
Based
on
data
obtained,
additional
studies
pharmacokinetics
pharmacodynamics
were
planned.
Язык: Английский